Introduction: In recent years, epidemiological studies have strongly related obesity with an increased risk of developing postmenopausal breast cancer. The aromatization of fatty tissue increases the levels of estradiol and adiponectin, which is correlated with the body mass index (BMI). It is of interest to investigate the effect of reducing BMI on estradiol, adiponectin, and IGF-1, as reducing BMI could be a new strategy to limit the risk of recurrence during the adjuvant treatment of breast cancer.
Objective: The aim of this study is to investigate the effect of reduced dietary fat on the levels of serum estradiol, adiponectin, and IGF-1 among postmenopausal Mexican women with breast cancer.
Methods: In this controlled clinical trial, 100 female patients were randomly divided into two groups and followed for six months. Group 1 (n = 50) was subjected to reduced dietary fat, whereas Group 2 (n = 50) was subjected to a control diet. The levels of serum estradiol and testosterone were determined using an enzyme-linked immunosorbent assay, whereas the concentrations of adiponectin and IGF-1 were determined using a radioimmunoassay.
Results: The patients subjected to reduced dietary fat showed a significant difference in BMI (27.93 ± 4.45 vs 26.05 ± 2.65; = 0.01) and waist circumference (99.92 vs 91.59 cm; = 0.0001) after the treatment. Moreover, a significant decrease in serum estradiol was observed (21.23 ± 14.32 vs 16.05 ± 10.25 ng/mL; < 0.001). The adiponectin concentration also decreased significantly (47.53 ± 12.19 vs 42.52 ± 12.34 µg/mL; = 0.004), while IGF-1 and testosterone did not show significant changes ( > 0.05). In addition, BMI had a relationship with serum adiponectin ( = -0.27; = 0.02) and estradiol ( = 0.37; = 0.001).
Conclusion: The current study shows that reducing BMI decreases serum estradiol and adiponectin. Large clinical trials are needed to investigate the role of adiponectin in breast cancer development in obese women.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447696 | PMC |
| http://dx.doi.org/10.2147/BCTT.S132602 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Acetate abates adipose-ovarian endocrinometabolic disturbance in experimentally induced polycystic ovarian syndrome.
Steroids
December 2024
Laboratory of Endocrinology, Department of Bioscience, Barkatullah University, Bhopal, Madhya Pradesh 462026, India.
Background: Besides ovarian dysfunction and infertility, individuals with polycystic ovarian syndrome (PCOS) also present a number of systemic disturbances including functional derangements in the adipose tissue which possibly aggravates the endocrinometabolic abnormality in PCOS. Epigenetic changes have been implicated in metabolic-related disorders including PCOS. However, its pathogenic involvement in adipose-ovarian dysfunction is unclear.
View Article and Find Full Text PDFRelationship of adiponectin, leptin and reproductive endocrine hormones with insulin resistance in polycystic ovary syndrome patients with normal BMI.
Gynecol Endocrinol
December 2024
Department of Gynaecology and Obstetrics, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Objective: This study aimed to analyze the correlation of adiponectin (APN) and leptin (LEP), reproductive endocrine hormones with insulin resistance (IR) in polycystic ovary syndrome (PCOS) patients with normal body mass index (BMI).
Methods: Totally 160 PCOS patients were categorized into the Normal BMI (BMI: 18.5-25 kg/m, = 62) and High BMI (BMI > 25 kg/m, = 98) groups.
Health implications of racial differences in serum growth differentiation factor levels among men with obesity.
Physiol Rep
December 2024
Division of Endocrinology Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas, USA.
Article Synopsis
- The study examined the role of Growth differentiation factor (GDF15) in relation to health markers in obese men of different racial and ethnic backgrounds.
- It involved 193 participants and assessed various health metrics including body composition, hormonal levels, and bone mineral density.
- Findings indicated that GDF15 levels were higher in non-African Americans than in African Americans, and its relations to glucometabolic status and body composition varied by ethnicity, highlighting potential racial differences in health risks.
Diabesity alters the protective effects of estrogens on endothelial function through adipose tissue secretome.
Free Radic Biol Med
November 2024
Grup de Metabolisme Energètic i Nutrició (GMEIN), Departament de Biologia Fonamental i Ciències de la Salut, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Universitat de les Illes Baleares, Ctra. Valldemossa, km 7.5, E-07122, Palma, Balearic Islands, Spain; Institut d'Investigació Sanitària de les Illes Baleares (IdISBa), Hospital Universitari Son Espases, E-07120, Palma, Balearic Islands, Spain; Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN, CB06/03/0043), Instituto de Salud Carlos III, E- 28029, Madrid, Spain.
Estrogens have a well-known protective role in the development of the metabolic syndrome. Nevertheless, recent epidemiological data question the cardioprotective effect of estrogens in obese and diabetic women. In this context, white adipose tissue (WAT) becomes dysfunctional, which has an impact on the cardiovascular system.
View Article and Find Full Text PDFLow dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT study): Study protocol of a randomized phase II biomarker trial in women at increased risk for breast cancer.
PLoS One
September 2024
Division of Cancer Prevention and Genetics, European Institute of Oncology IRCCS, Milan, Italy.
Background: Breast Cancer (BC) prevention strategies range from lifestyle changes such as increasing physical activity and reducing body weight to preventive drugs like tamoxifen, known to reduce BC incidence in high-risk women. Sex Hormone Binding Globulin (SHBG) is related to BC risk due to its ability to bind circulating estradiol at high affinity and to regulate estradiol action. A study protocol is presented based on the assessment of the effect of different interventions such as tamoxifen at 10 mg every other day (LDT), intermittent caloric restriction (ICR) two days per week, lifestyle intervention (LI, step counter use) and their combination on the modulation of SHBG and several other biomarkers associated to BC.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!